Our Company
CellantraTec is a preclinical biotechnology company building a reusable nonviral delivery platform and two co-lead oncology programs.
At A Glance
A Platform Built for Disciplined Scale
Two co-lead programs generate parallel preclinical evidence, creating more than one path to program-level value.
Shared delivery and development capabilities are intended to improve learning across programs.
Our Company
A Preclinical Biotechnology Company
Our development model is designed to convert platform learning into reproducible program evidence while keeping scientific progress distinct from complete-product validation.
“Progress is defined by reproducible evidence across development gates—not by completion of activities alone.” CEO,co-founder,Erick Bartel
→ RESEARCH FOCUS
Oncology Research
CellantraTech is advancing two preclinical oncology co-lead programs under a common evidence-driven development framework.
The portfolio includes two preclinical co-lead programs plus two research-stage, HLA-defined in vivo engineered-TCR programs.
